Uluru Inc. (OTCMKTS:ULUR) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Uluru Inc. (OTCMKTS:ULUR) reported that Sacks Michael Ivan has picked up 43,711,970 of common stock as of 2017-04-13.
The acquisition brings the aggregate amount owned by Sacks Michael Ivan to a total of 43,711,970 representing a 48.4% stake in the company.
For those not familiar with the company, ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
A glance at Uluru Inc. (OTCMKTS:ULUR)’s key stats reveals a current market capitalization of 4.26 Million based on 62.97 Million shares outstanding and a price at last close of $0.0677 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-29, Wallberg picked up 701,262 at a purchase price of $0.07. This brings their total holding to 825,519 as of the date of the filing.
On the sell side, the most recent transaction saw Oss unload 3,400,000 shares at a sale price of $0.16. This brings their total holding to 8,061,522.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Uluru Inc. (OTCMKTS:ULUR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Celgene Corp /de/ Picked Up Alliqua Biomedical Inc. (NASDAQ:ALQA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alliqua Biomedical Inc. (NASDAQ:ALQA) reported that Celgene Corp /de/ has picked up 8,025,194 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Celgene Corp /de/ to a total of 8,025,194 representing a 19.9% stake in the company.
For those not familiar with the company, Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
A glance at Alliqua Biomedical Inc. (NASDAQ:ALQA)’s key stats reveals a current market capitalization of 17.77 Million based on 35.11 Million shares outstanding and a price at last close of $0.599 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-27, Celgene picked up 4,000,000 at a purchase price of $0.50. This brings their total holding to 7,046,100 as of the date of the filing.
On the sell side, the most recent transaction saw Kalen unload 24,057,980 shares at a sale price of $0.04. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alliqua Biomedical Inc. (NASDAQ:ALQA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.